Table 3.
Severity of dysmenorrhoeic pain during treatment compared to the baseline levels
| Visit | Month 1* n (%) |
Month 2† n (%) |
Month 3 n (%) |
Month 4# n (%) |
Month 5 n (%) |
Month 6 n (%) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severity vs baseline | EE/CMA | EE/DRSP | EE/CMA | EE/DRSP | EE/CMA | EE/DRSP | EE/CMA | EE/DRSP | EE/CMA | EE/DRSP | EE/CMA | EE/DRSP |
| Much Decrease | 49 (55.1) | 32 (36.4) | 53 (59.6) | 41 (46.1) | 64 (71.9) | 58 (65.2) | 82 (92.1) | 72 (80.9) | 88 (98.9) | 85 (95.5) | 86 (96.6) | 85 (95.5) |
| Decrease | 14 (15.7) | 14 (15.9) | 29 (32.6) | 31 (34.8) | 23 (25.8) | 26 (29.2) | 7 (7.9) | 15 (16.9) | 1 (1.1) | 3 (3.4) | 2 (2.2) | 4 (4.5) |
| Not Change | 22 (24.7) | 40 (45.5) | 7 (7.9) | 16 (18) | 2 (2.2) | 3 (3.4) | 0 (0) | 2 (2.2) | 0 (0) | 1 (1.1) | 1 (1.1) | 0 (0) |
| Increase | 4 (4.5) | 2 (2.3) | 0 (0) | 1 (1.1) | 0 (0) | 2 (2.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
*p = 0.013; †p = 0.029; #p = 0.026; EE/CMA vs EE/DRSP